Suppr超能文献

间充质干细胞来源的人工修饰外泌体在肿瘤治疗中的潜在应用。

The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy.

作者信息

Song Yilin, Song Quanlin, Hu Daosheng, Sun Binwen, Gao Mingwei, Liang Xiangnan, Qu Boxin, Suo Lida, Yin Zeli, Wang Liming

机构信息

Engineering Research Center for New Materials and Precision Treatment Technology of Malignant Tumors Therapy, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.

Engineering Technology Research Center for Translational Medicine, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.

出版信息

Front Oncol. 2024 Jan 4;13:1299384. doi: 10.3389/fonc.2023.1299384. eCollection 2023.

Abstract

Mesenchymal stem cells (MSCs) have tumor-homing ability and play critical roles in tumor treatment, but their dual influences on tumor progression limit their therapeutic applications. Exosomes derived from MSCs (MSC-exosomes) exhibit great potential in targeted tumor treatment due to their advantages of high stability, low immunogenicity, good biocompatibility, long circulation time and homing characteristics. Furthermore, the artificial modification of MSC-exosomes could amplify their advantages and their inhibitory effect on tumors and could overcome the limit of tumor-promoting effect. In this review, we summarize the latest therapeutic strategies involving artificially modified MSC-exosomes in tumor treatment, including employing these exosomes as nanomaterials to carry noncoding RNAs or their inhibitors and anticancer drugs, and genetic engineering modification of MSC-exosomes. We also discuss the feasibility of utilizing artificially modified MSC-exosomes as an emerging cell-free method for tumor treatment and related challenges.

摘要

间充质干细胞(MSCs)具有肿瘤归巢能力,在肿瘤治疗中发挥着关键作用,但其对肿瘤进展的双重影响限制了其治疗应用。源自间充质干细胞的外泌体(MSC-外泌体)因其具有高稳定性、低免疫原性、良好的生物相容性、长循环时间和归巢特性等优势,在靶向肿瘤治疗中展现出巨大潜力。此外,对MSC-外泌体进行人工修饰可放大其优势及其对肿瘤的抑制作用,并可克服其促肿瘤作用的限制。在本综述中,我们总结了在肿瘤治疗中涉及人工修饰的MSC-外泌体的最新治疗策略,包括将这些外泌体用作纳米材料来携带非编码RNA或其抑制剂以及抗癌药物,以及对MSC-外泌体进行基因工程修饰。我们还讨论了将人工修饰的MSC-外泌体用作一种新兴的无细胞肿瘤治疗方法的可行性及相关挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c7f/10798044/7c45e59e4e12/fonc-13-1299384-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验